Medical gear maker Getinge beats Q3 profit estimates on pricing, product mix

By Reuters News

Oct 21 (Reuters) - Swedish medical equipment maker Getinge GETIb.ST reported third-quarter core earnings above market expectations on Wednesday, helped by a favourable product mix and disciplined pricing.

The maker of products for surgery, intensive care and sterilisation has spent the past year countering pressure from higher US import tariffs by raising prices, cutting costs and adjusting its supply chain.

  • Getinge's adjusted EBITA rose 18% to 1.28 billion Swedish crowns ($129 million) in the quarter. Analysts were expecting 1.19 billion crowns on average, a company-provided poll showed.

  • The group, which manufactures more than 60% of its products in the US, said its third-quarter adjusted EBITA margin benefited from 45 million crowns in tariff refunds and about 36 million crowns from year-on-year currency effects.

  • In July, Getinge received a refund of tariffs paid under International Emergency Economic Powers Act (IEEPA), US federal law, of about $36 million.

  • Getinge's quarterly orders rose 2.6% organically, marking an eleventh straight quarter of growth, driven by its Acute Care Therapies and Surgical Workflows units.

  • The company, whose products include ventilators and equipment for operating rooms, confirmed its forecast of organic sales growth of 3% to 5% for 2026, compared with 4.9% last year.




($1 = 9.9102 Swedish crowns)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.